Circulating Tumor Cell Market is Projected to Attain USD 5.9 Billion by 2031

Allied Market Research published a report, titled, "Circulating Tumor Cell Market by Technology (CTC Detection and Enrichment Method, CTC Direct Detection Methods, CTC Analysis), by Application (Clinical, Research), by End Users (Hospital and Clinics, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global circulating tumor cell industry generated $1.1 billion in 2021, and is anticipated to generate $5.9 billion by 2031, witnessing a CAGR of 18.0% from 2022 to 2031.

𝑹𝒆𝒒𝒖𝒆𝒔𝒕 𝑺𝒂𝒎𝒑𝒍𝒆 𝑪𝒐𝒑𝒚 𝒐𝒇 𝑹𝒆𝒑𝒐𝒓𝒕- https://www.alliedmarketresearch.com/request-sample/12283

𝑷𝒓𝒊𝒎𝒆 𝒅𝒆𝒕𝒆𝒓𝒎𝒊𝒏𝒂𝒏𝒕𝒔 𝒐𝒇 𝒈𝒓𝒐𝒘𝒕𝒉
Technological advancements in the field of diagnostics and treatment, rise in number of cancer cases, increase in awareness about CTCs and their detection in diagnosis of cancer, rise in research and development activities, and a rise in the number of clinical trials drive the growth of the global circulating tumor cell market. However, high cost associated with CTC testing owing to the high-quality instruments used for testing is expected to hinder the market growth. Moreover, rise in investment by key market players in developing countries, along with the rise in adoption of various strategies by the key players is anticipated to present new opportunities in the coming years.

𝐓𝐡𝐞 𝐂𝐓𝐂 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐞𝐧𝐫𝐢𝐜𝐡𝐦𝐞𝐧𝐭 𝐦𝐞𝐭𝐡𝐨𝐝𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐥𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐬𝐭𝐚𝐭𝐮𝐬 𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐨𝐮𝐭 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝

Based on technology, the CTC detection and enrichment methods segment held the highest market share in 2021, accounting for nearly three-fifths of the global circulating tumor cell market, and is estimated to maintain its leadership status throughout the forecast period. This is owing to the advantages that this method offers over direct detection, such as rapid test results, high purity of detection of cells, fast and easy cell isolation techniques such as immunocapture. However, the CTC analysis segment is projected to manifest the highest CAGR of 19.0% from 2022 to 2031, owing to the rise in developments in this segment, such as utilization of FISH and RT PCR techniques for CTC detection and cancer diagnosis.

𝑻𝒉𝒆 𝒄𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝒔𝒆𝒈𝒎𝒆𝒏𝒕 𝒕𝒐 𝒎𝒂𝒊𝒏𝒕𝒂𝒊𝒏 𝒊𝒕𝒔 𝒍𝒆𝒂𝒅𝒆𝒓𝒔𝒉𝒊𝒑 𝒔𝒕𝒂𝒕𝒖𝒔 𝒕𝒉𝒓𝒐𝒖𝒈𝒉𝒐𝒖𝒕 𝒕𝒉𝒆 𝒇𝒐𝒓𝒆𝒄𝒂𝒔𝒕 𝒑𝒆𝒓𝒊𝒐𝒅

Based on application, the clinical segment held the highest market share in 2021, accounting for more than two-thirds of the global circulating tumor cell market, and is estimated to maintain its leadership status throughout the forecast period. This is owing to the rise in the adoption of CTC detection techniques in cancer diagnosis along with a rise in the number of cancer cases including breast, prostate, and colon cancer. However, the research segment is projected to manifest the highest CAGR of 18.6% from 2022 to 2031, owing to an increase in research and development activities in CTC detection and diagnosis of cancer.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲- https://www.alliedmarketresearch.com/purchase-enquiry/12283

𝑻𝒉𝒆 𝒅𝒊𝒂𝒈𝒏𝒐𝒔𝒕𝒊𝒄 𝒄𝒆𝒏𝒕𝒆𝒓𝒔 𝒔𝒆𝒈𝒎𝒆𝒏𝒕 𝒕𝒐 𝒎𝒂𝒊𝒏𝒕𝒂𝒊𝒏 𝒊𝒕𝒔 𝒍𝒆𝒂𝒅 𝒑𝒐𝒔𝒊𝒕𝒊𝒐𝒏 𝒅𝒖𝒓𝒊𝒏𝒈 𝒕𝒉𝒆 𝒇𝒐𝒓𝒆𝒄𝒂𝒔𝒕 𝒑𝒆𝒓𝒊𝒐𝒅
Based on end users, the diagnostic centers segment accounted for the largest share in 2021, contributing to more than half of the global circulating tumor cell market, and is projected to maintain its lead position during the forecast period. This is owing to the large number of patient visits to diagnostic centers after the COVID-19 pandemic, as they offer precise testing and assist healthcare providers to decide the treatment regime. The report also discusses segments including hospitals and clinics, and others. However, the others segment would achieve the fastest CAGR of 18.5% through 2031, owing to the rise in funding offered to research centers and academic research institutes by government and non-government organizations.

𝑵𝒐𝒓𝒕𝒉 𝑨𝒎𝒆𝒓𝒊𝒄𝒂 𝒕𝒐 𝒎𝒂𝒊𝒏𝒕𝒂𝒊𝒏 𝒊𝒕𝒔 𝒅𝒐𝒎𝒊𝒏𝒂𝒏𝒄𝒆 𝒃𝒚 2031
Based on region, North America held the highest market share in terms of revenue in 2021, accounting for more than two-fifths of the global circulating tumor cell market, and is likely to dominate the market during the forecast period, owing to well-established healthcare infrastructure along with favorable policies offered by the government for diagnosis and treatment of cancer. However, the Asia-Pacific region is expected to witness the fastest CAGR of 20.2% from 2022 to 2031, owing to the presence of pharmaceutical companies in the region as well as growing purchasing power of populated countries, such as China, Japan and India.

𝑳𝒆𝒂𝒅𝒊𝒏𝒈 𝑴𝒂𝒓𝒌𝒆𝒕 𝑷𝒍𝒂𝒚𝒆𝒓𝒔: -
Miltenyi Biotec
Precision Medicine Group LLC
Menarini Group
SRI International
Biocept, Inc.
QIAGEN
Greiner AG
Sysmex Corporation
Thermo Fisher Scientific Inc.
STEMCELL Technologies Inc.
Trending Reports in Healthcare Industry-

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞- https://www.alliedmarketresearch.com/circulating-tumor-cell-market-A11918

𝑶𝒕𝒉𝒆𝒓 𝑻𝒓𝒆𝒏𝒅𝒊𝒏𝒈 𝑹𝒆𝒑𝒐𝒓𝒕𝒔 𝒊𝒏 𝑳𝒊𝒇𝒆 𝑺𝒄𝒊𝒆𝒏𝒄𝒆 𝑰𝒏𝒅𝒖𝒔𝒕𝒓𝒚-
𝑺𝒖𝒓𝒈𝒊𝒄𝒂𝒍 𝑮𝒍𝒖𝒆 𝑴𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/surgical-glue-market-A31580

𝑯𝒆𝒂𝒍𝒕𝒉 𝑪𝒐𝒂𝒄𝒉𝒊𝒏𝒈 𝑴𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/health-coaching-market-A13404

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com

Alied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.